左氧氟沙星治疗老年社区获得性肺炎临床研究

Levofloxacin in Treatment of Aged Patients with Community-acquired Pneumonia:Clinical Evaluation

目的评价左氧氟沙星治疗老年社区获得性肺炎的有效性和安全性。方法以左氧氟沙星静脉滴注为治疗组,头孢曲松静脉滴注为对照组,对两组治疗老年社区获得性肺炎的疗效和安全性进行随机对照观察。结果入选318例病例,可评价病例301例,治疗组可评价病例148 例,对照组153 例;治疗组和对照组的总有效率分别为95 .3%和92. 2%,治愈率分别为81 .8%和77. 8%;两组共分离细菌162 株,细菌清除率分别为88. 8%和85. 4%,不良反应发生率分别为7 .5%和3 .8%;实验室异常发生率分别为8 .8%和10 .0%;上述结果经统计学处理差异无显著性(P>0 .05)。结论左氧氟沙星静脉滴注治疗老年社区获得性肺炎疗效良好,不良反应发生较少且安全。

OBJECTIVE To compare the efficacy and safety of intravenous levofloxacin versus ceftriaxone in treatment of aged patients with community-acquired pneumonia(CAP). METHODS A prospective, comparative study was carried out in aged CAP patients. Patients received either levofloxacin 300mg twice daily intravenously or ceftriaxone 2.0g once for 7-10 days. RESULTS The 318 patients were enrolled in this study, 301 patients were evaluable, 148 patients in levofloxacin group and 153 patients in ceftriaxone. Clinical cure rates and total effective rates were 81.8%(121/148) and 95.3%(141/148) in levofloxacin group;77.8%(119/153) and 92.2%(141/153) in control group; the bacterial eradication rate being 88.8%(71/80) and 85.4%(70/82), respectively. The clinical adverse effect rates were 7.5%(12/159) and 3.8%(6/159),while abnormal laboratory tests were 8.8%(14/159) and 10.0%(16/159) in the two groups respectively. No significant difference of the above figures between the two groups were found,P>0.05. CONCLUSIONS Levofloxacin therapy is as effective as ceftriaxone in treatment of aged CAP, adverse effects are transient in both groups.